Hong Kong – French Science Festival activities enable public to explore science in sport (with photos)
French Science Festival activities enable public to explore science in sport (with photos)
******************************************************************************************
To tie in with the theme of this year’s French Science Festival “Sport and Science: from Health to Performance”, the Science Promotion Unit of the Hong Kong Science Museum (HKScM) is collaborating with the Consulate General of France in Hong Kong and Macau to roll out a series of activities from tomorrow (November 10) to November 27. They include the “Science at the Service of Medals” exhibition, a film screening, a conference and a panel discussion at the HKScM, so that members of the public can better understand the relationship between science and health as well as athletes’ performances.
Addressing the opening ceremony of the exhibition today (November 9), the Deputy Director of Leisure and Cultural Services (Culture), Miss Eve Tam, said that the French Science Festival provides an inspiring opportunity for schools and the public to appreciate the significance of sports in people’s daily lives and the interconnection between science and sports. Other officiating guests included the Consul General of France in Hong Kong and Macau, Mrs Christile Drulhe, and the Museum Director of the HKScM, Mr Lawrence Lee.
The “Science at the Service of Medals” exhibition designed by the Cité des sciences et de l’industrie, showcases the collaborative efforts of scientists across diverse disciplines who develop equipment to enhance speed, utilise virtual reality training to reduce fatigue, and individualise training regimens through physiology studies to empower athletes. The virtual reality experience of “A Taste for Risk” will also be presented at the exhibition venue. Through a transmedia project that combines a documentary and virtual reality with three French athletes, participants will be able to immerse themselves in four extreme sports, including bodyboarding, wingsuit flying, free-diving, and snowboarding. They can gain an unparalleled experience and feel the thrill of pushing limits.
Besides the exhibition, the HKScM will also launch a series of feature programmes. They include a film screening of the animated comedy “Les Triplettes de Belleville”, which received two Oscar nominations, on November 11 at 4pm. The Champions Conference will be held on November 18 at 6pm, when the coach of the Hong Kong, China Fencing Team, Mr Grégory Koenig, and Hong Kong, China Paralympic fencer athlete, Ms Alison Yu, will share their journeys leading towards winning Olympic and Paralympic medals. The Hong Kong break dancer who competed in the Asian Games, B-Boy C Plus, will also give a performance. There will be a nutrition panel discussion on November 26 at 3pm, where Sport Nutrition & Monitoring Manager, Hong Kong Sports Institute Dr Margaret Kuo, together with a senior dietian and a sports science officer, will discuss with participants the relationship between nutrition and health, as well as sport performances. Online registration for the three programmes mentioned above has started. There will be limited quotas and are available on a first-come, first-served basis. For registration, please visit www.spu.hk/en/cards/french-science-festival-2023/, or call 2732 3232 for enquiries.
The exhibition and programmes are jointly presented by the Leisure and Cultural Services Department and the Consulate General of France in Hong Kong and Macau, and jointly organised by the Science Promotion Unit of the HKScM and the Consulate General of France in Hong Kong and Macau.
Moolec Science SA (NASDAQ:MLEC) a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming, today reported its Business Update for the fourth quarter of Fiscal Year 2023 ended June 30, 2023. The main highlights of the Company’s business update are as follows: – Piggy Sooy(TM): introducing a soybean platform that can produce high amounts of pork protein. “Looking back, I am incredibly proud of what Moolec has accomplished. We set ambitious goals, and our unwavering commitment to innovation and excellence has allowed us to not only meet but exceed our objectives. Our team’s relentless dedication and innovations achieved unprecedented scientific results,” stated Gastón Paladini, Chief Executive Officer and Co-Founder of Moolec Science. “This year, Moolec achieved important milestones that not only reflect our technological ability but also our investment backing. In addition to the $10 million raised during Fiscal Year 2023, we were able to commit $30 million from strategic investors in a challenging financial market environment. These commitments will drive Moolec´s business model forward through additional liquidity and enhanced capabilities,” said José López Lecube, Chief Financial Officer and Director of Moolec Science. He added, “Our sources of financial support and funding avenues are adequate and work to support our commitment to innovate in the food industry.” For a full version of Moolec’s fourth quarter Fiscal Year 2023 Business Update, click here. https://pr.report/kLEIeFQN Management will host a Conference Call and question-and-answer session, which will be accompanied by a presentation available during the webinar. To access the call, please use the following information: Please connect 5 minutes prior to the start time to register and join. A replay and the pdf version of the presentation will be available approximately two hours after the conclusion of the live event via the company’s Investor Relations website. About Moolec Science SA Moolec is a science-based ingredient company leader in the use of Molecular Farming technology for food. The Company’s mission is to create unique food ingredients by engineering plants with animal protein genes. Its purpose is to redefine the way the world produces animal-based food, for good and for all. Moolec’s technological approach aims to have the cost structure of plant-based solutions with the organoleptic properties and functionality of animal-based ones. Moolec’s technology has been under development for more than a decade and is known for pioneering the production of a bovine protein in a crop for the food industry. The Company’s product portfolio and pipeline leverages the agronomic efficiency of broadly used target crops, like soybean and safflower. Recently, it acquired plant-based ingredient capabilities to consolidate Molecular Farming Technology. Moolec has a growing international patent portfolio (25, both granted and pending) for its Molecular Farming technology. The Company is run by a diverse team of Ph.Ds and Food Insiders, and operates in the United States, Europe, and South America. Forward-Looking Statements This press release contains “forward-looking statements.” Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec’s business and other risks and uncertainties, including those included under the header “Risk Factors” in the Moolec’s Annual Report on Form 20 – Filed with the U.S. Securities and Exchange Commission (“SEC”), as well as Moolec’s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements. Contact Information Moolec Science SA (NASDAQ:MLEC; “Company”; “Moolec”), a science-based food ingredient company, announced today that it has entered into agreements to issue a convertible note due 2026 to Grupo Insud (“Insud”) in a principal amount of approximately US $21 million (the “Insud Convertible Note”) with a strike price of US $6.00 per share. The Insud Convertible Note will be issued against a cash payment of US $10 million and in-kind contributions to be made by Insud to Moolec. In-kind contributions include credits to access Insud’s state-of-the-art industrial capabilities, operational services, and the incorporation of Joint Venture participation, started with Moolec in 2021. At maturity, Moolec will hold the option to deliver ordinary shares, cash, or a combination of cash and ordinary shares. This transaction follows Moolec’s previous announcement that it entered into a Memorandum of Understanding with Bioceres Crop Solutions (NASDAQ:BIOX; “BIOX”) that secures the supply of approximately 15,000 tons of HB4® soybeans (the “BIOX Supply Agreement”) that may be upsized for a similar volume. The BIOX Supply Agreement will be paid through the issuance of a convertible note (the “BIOX Convertible Note” and together with the Insud Convertible Note, the “Convertible Notes”) on arms-length terms to the Insud Convertible Note. Under the BIOX Supply Agreement, Bioceres Crop Solutions will engage with Generation HB4® farmers to source and deliver to Moolec soybeans with a sustainability-linked premium, which are produced under regenerative agricultural practices, minimizing water, carbon, and chemical footprints. The Generation HB4® program is an identity-preserved farming program that utilizes HB4® drought-tolerance technology to enable soybean-wheat crop rotations and improve agricultural sustainability. Together, the Convertible Notes total approximately US $30 million of cash and in-kind contributions that include soybean inventories, operational services, and the acquisition of Joint Venture equity. “We are thrilled to announce these agreements, which highlight the importance of incorporating strategic players as shareholders. We are very proud to count with Insud, a biotech leader in life sciences industries, and Bioceres Crop Solutions, a top-notch ag-biotech player, as key partners for the upcoming stages of the Company’s development,” said Gastón Paladini, Moolec’s Chief Executive Officer. “We all share the common purpose to redefine the way we produce animal-based food, for good and for all. These engagements reinforce our vision and our shareholders’ long-term commitments, while motivating Moolec´s Team to achieve the milestones to come,” concluded the CEO. “We are proud to support Moolec with this transaction and throttle the evolution of its pipeline to bolster Moolec as a technology leader in the food industry. Our constant pursuit of excellence and innovation drives our partnership policies, not only by providing funding but also by offering our experience as an innovative company in the biotechnology space. It is Insud’s purpose to foster new and better ways of improving people’s lives,” said Manuel Sobrado, Executive Director of Grupo Insud in Argentina. “This capital raise strengthens our financial position and allows us to accelerate our business model in a challenging financial market. The notes provide healthy optionality for Moolec to convert into common shares or cash in three years’ time,” said José López Lecube, Moolec’s Chief Financial Officer. “Cash proceeds will be used to continue funding key R&D projects and in-kind contributions will secure the needed working capital to ramp up our commercialization plan and product development initiatives,” he added. About the Convertible Notes The Insud Convertible Note will mature in 36 months after they are issued, will initially accrue interest 10.0% p.a. and include a “payment-in-kind” feature. If the trading price of Moolec’s ordinary shares exceeds the strike price of US $6.00 per ordinary share (the “Strike Price”) for 10 trading days, Insud will have the option to exercise the early conversion option pursuant to which the principal amount outstanding under the Insud Note may be converted into ordinary shares of Moolec at the Strike Price. The Strike Price represents a premium of approximately 100% of the 20-day VWAP of Moolec’s ordinary shares. At maturity, Moolec has the option to convert the principal amount outstanding under the Insud Note into ordinary shares. In connection with Insud’s early conversion option and Moolec’s optional conversion at maturity, Moolec may deliver ordinary shares, cash, or a combination of cash and ordinary shares to Insud. The in-kind contributions to be made by Insud to Moolec are subject to the completion of an independent appraisal procedure in accordance with Luxembourg law. The BIOX Convertible Note is expected to be issued on substantially similar terms as the Insud Convertible Note. About Moolec Science SA Moolec is a science-based ingredient company leader in the use of Molecular Farming technology for food. The Company’s mission is to create unique food ingredients by engineering plants with animal protein genes. Its purpose is to redefine the way the world produces animal-based food, for good and for all. The Company’s technological approach aims to have the cost structure of plant-based solutions with the organoleptic properties and functionality of animal-based ones. Moolec’s technology has been under development for more than a decade and is known for pioneering the production of a bovine protein in a crop for the food industry. The Company’s product portfolio and pipeline leverages the agronomic efficiency of broadly used target crops, like soybean, pea, and safflower. Recently, Moolec acquired plant-based ingredient capabilities to consolidate its Molecular Farming Technology. Moolec has a growing international patent portfolio (25, both granted and pending) for its Molecular Farming technology. The Company is run by a diverse team of Ph.Ds and Food Insiders, and operates in the United States, Europe, and South America. About Grupo Insud Grupo Insud is a global company focused on innovation, sustainability, and development in different industries such as pharma, agribusiness, and renewable energy. With operations in over 40 countries and more than 8,000 people committed to pursue excellence and undertake new challenges. About Bioceres Crop Solutions Corp. Bioceres Crop Solutions Corp. (NASDAQ:BIOX) is a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change. To do this, Bioceres’ solutions create economic incentives for farmers and other stakeholders to adopt environmentally friendlier production practices. The company has a unique biotech platform with high-impact, patented technologies for seeds and microbial ag-inputs, as well as next-generation Crop Nutrition and Protection solutions. Through its HB4® program, the Company is bringing digital solutions to support growers’ decisions and provide end-to-end traceability for production outputs. Forward-Looking Statements This press release contains “forward-looking statements.” Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec’s business and other risks and uncertainties, including those included under the header “Risk Factors” in the Moolec’ Annual Report on Form 20-Filled with the U.S. Securities and Exchange Commission (“SEC”), as well as Moolec’s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements. Contact Information Catalina Jones, Chief of Staff & Sustainability, comms@moolecscience.com Moolec Science SA ((NASDAQ:MLEC) “Company”; “Moolec”), a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming technology, announced today an outstanding achievement in its Meat Replacements Program for the Soybean platform, as its new “Piggy Sooy” produced a significantly high amount of pork protein. The animal protein reached a high expression level up to 26.6% of total soluble protein in soy seeds, 4x higher than initially projected by the Company. The result can be directly observed due to the pink color of Moolec’s soybeans, the same color as the pig (access the picture by clicking here https://moolecscience.com/#piggysooy ). After this achievement, the Company’s soybean platform was renamed “Piggy Sooy”. The breakthrough accomplishment has led Moolec to file a new patent utilizing a novel approach aiming to provide the Company with a frictionless regulatory pathway going forward. Moolec’s CEO & Co-Founder Gaston Paladini said: “Piggy Sooy represents tangible and visual proof that Moolec’s technology has the capacity to achieve significant yields in plants to produce meat proteins. With this groundbreaking achievement, Moolec consolidates its position as a category creator and a pioneer in Molecular Farming for the food industry. Our plant biology team is writing the history of science in food, I couldn’t be prouder of them.” This scientific milestone consolidates the Molecular Farming path as one of the most valuable alternative technologies to produce animal proteins, given that plants can function as animal protein factories in a more efficient manner than initially expected. This enhanced efficiency of plants has the potential to improve the economics of the Company’s business model. Moolec Science is producing several meat proteins in plants as functional ingredients to improve the taste, appearance, texture, and nutrition of meat alternatives. Due to its enhanced functionality and final application, the Company also highlighted that these food ingredients could also be potentially commercialized within the ~$600 billion traditional processing meat industry. Amit Dhingra, Ph.D., Chief Science Officer of Moolec said: “This achievement opens up a precedent for the entire scientific community that is looking to achieve high levels of protein expression in seeds via Molecular Farming.” He further emphasized: “Moolec has developed a unique, successful, and patentable platform for the expression of highly valuable proteins in the seeds of economically important crops such as soybeans. This platform has the potential to be used across a wide variety of proteins of interest for a broad range of industries, such as the pharma, cosmetic, diagnostic reagents, and other food industries.” About Moolec Science SA Moolec is a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The Company’s technological approach aims to have the cost structure of plant-based solutions with the organoleptic properties and functionality of animal-based ones. Moolec’s technology has been under development for more than a decade and is known for pioneering the production of a bovine protein in a crop for the food industry. The Company’s product portfolio and pipeline leverages the agronomic efficiency of broadly used target crops, like safflower, soybean, and pea. Moolec has a growing international patent portfolio (24, both granted and pending) for its Molecular Farming technology. The Company is run by a diverse team of Ph.Ds and Food Insiders, and operates in the United States, Europe, and South America. For more information, visit moolecscience.com. Forward-Looking Statements This press release contains “forward-looking statements.” Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec’s business and other risks and uncertainties, including those included under the header “Risk Factors” in the Moolec’ Annual Report on Form 20-Filled with the U.S. Securities and Exchange Commission (“SEC”), as well as Moolec’s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements. Contact Information Martin Taraciuk Michael Bowen Edmond Lococo Related Files Moolec Science SA (NASDAQ:MLEC) (“Company”; “Moolec”), a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming, announced today it has entered into a Share Purchase Agreement (“Agreement”) with Nomura Securities International, Inc. (“Nomura”). The Agreement provides for a committed equity financing facility under which the Company has the option, but not the obligation, to sell up to the equivalent of $50 million in aggregate gross purchase price of its ordinary shares to Nomura over a 36-month period, subject to the terms of the Agreement. The Company intends to use the proceeds from any future sales of securities under the financing facility, if it is utilized, for general corporate purposes. “We are pleased to partner with Nomura and secure this financing facility,” said Jose Lopez Lecube, Moolec Science’s Chief Financial Officer. “This new understanding provides Moolec with enhanced financial flexibility to continue driving forward our Molecular Farming Platform and portfolio of products,” he concluded. Further details are contained in a Current Report on Form 6-K that was filed with the Securities and Exchange Commission today. About Moolec Science SA Moolec is a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The Company’s technological approach aims to have the cost structure of plant-based solutions with the organoleptic properties and functionality of animal-based ones. Moolec’s technology has been under development for more than a decade and is known for pioneering the production of a bovine protein in a crop for the food industry. The Company’s product portfolio and pipeline leverages the agronomic efficiency of broadly used target crops, like safflower, soybean, and pea. Moolec has a growing international patent portfolio (23, both granted and pending) for its Molecular Farming technology. The Company is run by a diverse team of Ph.Ds and Food Insiders, and operates in the United States, Europe, and South America. For more information, visit www.moolecscience.com. Forward-Looking Statements This press release contains “forward-looking statements.” Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec Science S.A. (“Moolec”) are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec’s business and other risks and uncertainties, including those included under the header “Risk Factors” in the Form F-1 Registration Statement filed with the U.S. Securities and Exchange Commission (“SEC”), as well as Moolec’s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements. Contact Information Martin Taraciuk Michael Bowen Related Files
Moolec Science Presents Fourth Quarter FY 2023 Business Update
— The animal protein reached high expression levels of up to 26.6% of total soluble protein in soy seeds, 4x higher than initially projected by the Company.
— Completed Regulatory Status Review submission from USDA-APHIS and engaged in pre-submission discussions with FDA.
— New patent was successfully filed.
– Moolabs: New Moolec’s Molecular Biology Lab in Texas A&M University Bioscience Business Accelerator.
– GLASO: 2023 safflower campaign finished with ~50% above average crop yields.
– Capital Raise: ~$30 million from strategic investors in cash and in-kind contributions.
– Date: Monday October 23, 2023- Time: 09:00 am ET
– Link to join the webinar: https://us06web.zoom.us/j/84198066199
– Dial In: +1 507 473 4847 US | Webinar ID: 841 9806 6199
– International numbers available: https://us06web.zoom.us/u/kbOMXArmP
Catalina Jones, Chief of Staff & Sustainability, comms@moolecscience.com
Martín Taraciuk, Investor Relations, ir@moolecscience.com
Michael Bowen, ICR, LLC moolecir@icrinc.com
Topic: Press release summaryMoolec Science Announces US $30 Million Capital Raise With Strategic Investors
Martín Taraciuk, Investor Relations, ir@moolecscience.com
Michael Bowen, ICR, LLC, moolecir@icrinc.com
Topic: Press release summaryMoolec Science Presents ‘Piggy Sooy’, a Soybean Platform That Can Produce Significantly High Amounts of Pork Proteins
Piggy Sooy
Catalina Jones
Chief of Staff & Sustainability
comms@moolecscience.com
Investor Relations
ir@moolecscience.com
ICR, LLC
moolecir@icrinc.com
ICR
edmond.lococo@icrinc.com
Moolec Science Presents “Piggy Sooy”, A Soybean Platform That Can Produce Significantly High Amounts Of Pork Proteins.pdf
https://cdn.newswire.com/files/x/d9/db/f425d1320c1028c17fdceea2e8f4.pdf
Topic: Press release summaryMoolec Science Secures Up to $50 Million in Committed Equity Financing With Nomura
Catalina Jones
Chief of Staff & Sustainability
comms@moolecscience.com
Investor Relations
ir@moolecscience.com
ICR, LLC
moolecir@icrinc.com
Moolec Science Secures up to $50 Million Dollars in Committed Equity Financing with Nomura – 2023.04.17.pdf
https://cdn.newswire.com/files/x/a8/e1/bf62a363bcdd61ad9685397e5d2a.pdf
Ads
